Dynavax Technologies (DVAX) 10-K2014 FY Annual report

Filed: 5 Mar 15, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: ACC, accrual, adaptive, affirmative, annum, anti, antitumor, ATM, balloon, begun, bioavailability, body, borrow, BRAF, broader, Celgene, checkpoint, Chemotherapeutic, codified, distinct, drawn, drew, efficient, endosomal, family, greatly, hypothetical, IIa, immaterial, immunotherapeutic, intratumorally, Journal, killing, MEK, military, modest, mouse, multivesicular, NASH, nonalcoholic, Notwithstanding, occupational, opposition, output, PDC, PDUFA, permanently, pharmacodynamic, plasmacytoid, play, postpone, preliminary, prepayment, Prescription, prespecified, prime, proceed, profile, prophylactic, radiation, rationale, reassessed, regained, release, reply, resolution, retroactively, rHBsAg, SAC, science, scleroderma, secondary, solid, sought, sputum, stable, sublet, suggest, systematic, team, theory, tranche, transgenic, transmembrane, twelve, unchanged, unlawfully, unpaid, untreated, User, vital, weekly

Removed: abnormal, acid, allergic, Aspire, ASU, bargaining, bearing, beta, biodefense, Biogen, build, cancelled, carcinoma, carry, Coley, collective, committed, commonly, death, dedicated, Deerfield, deoxyribonucleic, Designation, dina, dino, discontinued, diversified, enhance, exist, explore, feasibility, fight, flow, gave, Genentech, generalized, generic, Glaxo, Hansenula, hepatocellular, Idec, immunocompromised, immunosuppressive, Imputed, incremental, inhibit, insolvency, join, kidney, knowledge, linked, Marketplace, martin, MedImmune, Mellon, molecular, Morgan, netted, noncontrolling, obese, onset, overallotment, papilloma, parent, partnering, pertaining, Poor, possessing, potency, potent, reacquisition, reclassified, redirect, reducing, regimen, remeasured, renal, reprogramming, respiratory, retained, Roche, separated, spread, Standstill, subset, thereof, tyler, universal, versatility, viral, Wedbush, window, yeast

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

DVAX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 12.1

	For the Year Ended December 31,
	2014			2013			2012			2011			2010
	(In thousands)
Earnings
Loss from continuing operations before income taxes	$	(90,722	)	$	(66,720	)	$	(69,949	)	$	(48,597	)	$	(57,308	)
Fixed charges		438			509			2,795			2,420			2,341
Amount attributable to noncontrolling interest in Symphony Dynamo, Inc.		-			-			-			-			-
Earnings, as defined	$	(90,284	)	$	(66,211	)	$	(67,154	)	$	(46,177	)	$	(54,967	)

Fixed charges:
Interest expense	$	(35	)	$	-		$	2,351		$	1,957		$	1,654
Estimated interest component of rent expenses		473			509			444			463			687
Total fixed charges	$	438		$	509		$	2,795		$	2,420		$	2,341
Preferred stock deemed dividend		-			8,469			-			-			-
Total fixed charges and preferred dividend	$	438		$	8,978		$	2,795		$	2,420		$	2,341

Deficiency of earnings available to cover fixed charges and preferred stock dividends⁽¹⁾	$	(90,722	)		(75,189	)		(69,949	)		(48,597	)		(57,308	)

(1): Adjusted earnings, as described above, were insufficient to cover fixed charges in each year.